21 天前 - … patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and
neck … with standard-of-care pembrolizumab-based regimens represents an important unmet …

58 天前 - … (cetuximab … in patients receiving pembrolizumab plus epacadostat in this study
(29%), which was consistent with a phase 3 trial of epacadostat plus pembrolizumab in patients …

59 天前 - … AE in patients receiving pembrolizumab plus epacadostat in this … plus pembrolizumab
in patients with unresectable or … , or cetuximab for recurrent or metastatic head‑and‑neck …

71 天前 - … or without targeted therapies such as cetuximab, an anti-… and chemotherapy,
including cetuximab, methotrexate, and … Initially, in second-line patients, the immune checkpoint …

116 天前 - … Head and Neck Society meeting. Methods: A phase 1b/2 open-label study of pts with
recurrent locally advanced (rLA) and/or metastatic (m… anti-PD-1 (pembrolizumab) therapy (…

145 天前 - … Patients and Methods: R/M HNSCC patients who were treated with cisplatin, 5-fluorouracil
plus cetuximab (EPF) or pembrolizumab (PPF) as first-line treatment were included …

191 天前 - … once daily plus pembrolizumab 200 mg IV every 3 weeks (≤35 pembrolizumab
cycles)… (investigator's choice of docetaxel, paclitaxel, cetuximab, or capecitabine), or oral …

298 天前 - … pembrolizumab and pembrolizumab-chemotherapy were not better than those for
cetuximab… : weekly paclitaxel (80 mg/m 2 ) plus cetuximab (400 mg/m 2 loading dose followed …

326 天前 - … inhibitors (ICIs), herein pembrolizumab and nivolumab, have an essential role in
the treatment of recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN)…

326 天前 - … plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head
and neck … Dosages, regimens and references to clinical data are as follows: Pembrolizumab …